Metraipolis › archive › dc_4e0815ff2ee4

Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance — Europe PMC PMID:41567666

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41567666
DOI: 10.3389/fmed.2025.1709089
License (as archived): solo-consultazione
Archived: 2026-11-07T00:53:42.826Z
SHA-256 of the archived text: b04c13f30fedbe08a96297090f443c0a1f546f3f7e84ab262f0943e36400d45d
Stable URL of this page: https://metraipolis.com/documento/dc_4e0815ff2ee4

How to cite

Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance — Europe PMC PMID:41567666 — Europe PMC (en), https://europepmc.org/article/MED/41567666 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4e0815ff2ee4 (Metraipolis archive dc_4e0815ff2ee4, sha256 b04c13f30fedbe08a96297090f443c0a1f546f3f7e84ab262f0943e36400d45d)

BibTeX

@misc{dc4e0815ff2ee4,
  title = {Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance — Europe PMC PMID:41567666},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41567666},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4e0815ff2ee4; sha256 b04c13f30fedbe08a96297090f443c0a1f546f3f7e84ab262f0943e36400d45d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41567666. Agents can read the archived copy with the MCP tool read_document.